An anti-MIF mAb that has been studied in Phase II PoC in cancer patients as well as anti-CD74 mAb that is in clinical phase and would allow simultaneous blockade of MIF and DDT signaling are of even more relevant for more rapid application in the clinical setting [6]. This evidence concerns the gene MIF and cancer.